Allarity Therapeutics, Inc. Research and Development Expense
Allarity Therapeutics, Inc. (ALLR) reported Research and Development Expense of $1.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- Allarity Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $1.34M, a 42.05% decline year-over-year.
- Allarity Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $1.30M, a 7.56% decline year-over-year.
- Allarity Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $1.67M, a 9.37% decline year-over-year.
- Allarity Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $1.20M, a 17.83% increase year-over-year.
- Allarity Therapeutics, Inc. research and development expense for fiscal 2025 was $6.60M, a 8.28% increase from fiscal 2024.
- Allarity Therapeutics, Inc. research and development expense for fiscal 2024 was $6.10M, a 14.18% decline from fiscal 2023.
- Allarity Therapeutics, Inc. research and development expense for fiscal 2023 was $7.10M, a 2.50% increase from fiscal 2022.
- Allarity Therapeutics, Inc. research and development expense for fiscal 2022 was $6.93M, a 51.18% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.34M 10-Q · filed 2026-08-14 | $2.64M 10-Q · filed 2026-08-14 | $4.32M derived: sum of 3 quarters · filed 2026-08-14 | $5.52M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $1.30M 10-Q · filed 2026-05-15 | $2.97M derived: sum of 2 quarters · filed 2026-05-15 | $4.17M derived: sum of 3 quarters · filed 2026-05-15 | $6.50M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.88M derived: sum of 2 quarters · filed 2026-03-30 | $5.20M derived: sum of 3 quarters · filed 2026-08-14 | $6.60M 10-K · filed 2026-03-30 | ||
| 2025-09-30 | $1.20M 10-Q · filed 2025-11-14 | $3.52M derived: sum of 2 quarters · filed 2026-08-14 | $4.93M 10-Q · filed 2025-11-14 | $6.77M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | $2.32M 10-Q · filed 2026-08-14 | $3.72M 10-Q · filed 2026-08-14 | $5.57M derived: sum of 3 quarters · filed 2026-08-14 | $6.59M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $1.40M 10-Q · filed 2026-05-15 | $3.25M derived: sum of 2 quarters · filed 2026-05-15 | $4.27M derived: sum of 3 quarters · filed 2026-05-15 | $5.33M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $2.87M derived: sum of 2 quarters · filed 2026-03-30 | $3.93M derived: sum of 3 quarters · filed 2026-03-30 | $6.10M 10-K · filed 2026-03-30 | ||
| 2024-09-30 | $1.02M 10-Q · filed 2025-11-14 | $2.08M derived: sum of 2 quarters · filed 2025-11-14 | $4.25M 10-Q · filed 2025-11-14 | $6.87M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $1.06M 10-Q · filed 2025-08-15 | $3.23M 10-Q · filed 2025-08-15 | $5.85M derived: sum of 3 quarters · filed 2025-08-15 | $7.80M derived: sum of 4 quarters · filed 2025-08-15 | ||
| 2024-03-31 | $2.17M 10-Q · filed 2025-05-09 | $4.79M derived: sum of 2 quarters · filed 2025-05-09 | $6.74M derived: sum of 3 quarters · filed 2025-05-09 | $7.85M derived: sum of 4 quarters · filed 2025-05-09 | ||
| 2023-12-31 | $2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $4.57M derived: sum of 2 quarters · filed 2025-03-31 | $5.68M derived: sum of 3 quarters · filed 2025-03-31 | $7.10M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $1.95M 10-Q · filed 2024-11-14 | $3.05M derived: sum of 2 quarters · filed 2024-11-14 | $4.48M 10-Q · filed 2024-11-14 | $5.42M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $1.10M 10-Q · filed 2024-08-05 | $2.53M 10-Q · filed 2024-08-05 | $3.47M derived: sum of 3 quarters · filed 2024-08-05 | $6.48M derived: sum of 4 quarters · filed 2024-08-05 | ||
| 2023-03-31 | $1.43M 10-Q · filed 2024-05-14 | $2.37M derived: sum of 2 quarters · filed 2024-05-14 | $5.37M derived: sum of 3 quarters · filed 2024-05-14 | $7.07M derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $941.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $3.94M derived: sum of 2 quarters · filed 2024-03-08 | $5.64M derived: sum of 3 quarters · filed 2024-03-08 | $6.93M 10-K · filed 2024-03-08 | ||
| 2022-09-30 | $3.00M 10-Q · filed 2023-11-14 | $4.70M derived: sum of 2 quarters · filed 2023-11-14 | $5.99M 10-Q · filed 2023-11-14 | $15.51M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $1.70M 10-Q · filed 2023-08-14 | $2.98M 10-Q · filed 2023-08-14 | $12.51M derived: sum of 3 quarters · filed 2023-08-14 | $13.86M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $1.29M 10-Q · filed 2023-05-11 | $10.81M derived: sum of 2 quarters · filed 2023-05-11 | $12.17M derived: sum of 3 quarters · filed 2023-05-11 | $14.45M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $9.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $10.88M derived: sum of 2 quarters · filed 2023-03-13 | $13.16M derived: sum of 3 quarters · filed 2023-03-13 | $14.20M 10-K · filed 2023-03-13 | ||
| 2021-09-30 | $1.35M 10-Q · filed 2022-11-14 | $1.57M 10-Q · filed 2021-11-23 | $3.63M derived: sum of 2 quarters · filed 2022-11-14 | $4.67M 10-Q · filed 2022-11-14 | $5.33M 10-Q · filed 2021-11-23 | $6.55M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $2.28M 10-Q · filed 2022-10-07 | $3.53M 10-Q · filed 2022-10-07 | $5.20M derived: sum of 3 quarters · filed 2022-10-07 | $5.98M derived: sum of 4 quarters · filed 2022-10-07 | ||
| 2021-03-31 | $1.25M 10-Q · filed 2022-05-27 | $2.92M derived: sum of 2 quarters · filed 2022-05-27 | $3.70M derived: sum of 3 quarters · filed 2022-05-27 | |||
| 2020-12-31 | $1.67M derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-05-17 | $2.45M derived: sum of 2 quarters · filed 2022-05-17 | $4.22M 10-K · filed 2022-05-17 | |||
| 2020-09-30 | $785.00K 10-Q/A · filed 2022-05-17 | $1.01M 10-Q · filed 2021-11-23 | $2.55M 10-Q/A · filed 2022-05-17 | $3.23M 10-Q · filed 2021-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |